Skip to content
Bored Studies
RecruitingPhase 2

A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo

Novartis Pharmaceuticals · NCT07431177

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–99 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
210
US sites recruiting
24
Study start
March 9, 2026
Record last updated
October 13, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into the confirmatory Phase 3 program.

Being studied: GIA632; Placebo

Conditions: Non-segmental Vitiligo

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Signed informed consent must be obtained prior to participation in the study
  • Male or female as assigned at birth ≥ 18 years of age at the time of screening
  • Individuals with a diagnosis of non-segmental vitiligo and confirmation of diagnosis through physical examination by the investigator
  • Non-segmental vitiligo, as assessed at screening, as
  • ≥ 0.5% Body Surface Area (BSA) on the face and F-VASI score ≥ 0.5
  • ≥ 3% BSA on non-facial areas (minimum of 3% should be calculated in addition to hands and feet) and T-VASI score = 3 to 60

Exclusion Criteria

  • Individuals unable or unwilling to follow the study procedures and/or to complete the study-related questionnaires
  • Presence of segmental or mixed vitiligo, or other skin comorbidities that may interfere with study assessments (e.g., hypopigmented mycosis fungoides, genetic diseases with pigmentary aberrations [such as piebaldism, Waardenburg, etc.], chemical- or druginduced leukoderma, etc.)
  • Previous exposure to biologic drugs directly targeting IL-15 or IL-15 receptors
  • Individual who previously attempted or completed depigmentation therapy for NSV
  • Use of prohibited medication \& treatments. Other protocol-defined inclusion/exclusion criteria may apply

Recruiting US locations

  • Cahaba Derm and skin hlth ctr 27

    Birmingham, AL 35244

    Site contact: Wes Booth · +1 205 778 1564 · wbooth@cahabaderm.com

  • First OC Dermatology

    Fountain Valley, CA 92708

    Site contact: Keiry Espinoza · +1 714 531 2966 · kespinoza@dermcaremgt.com

  • MedDerm Associates

    San Diego, CA 92103

    Site contact: Kristian Cadag · +1 619 243 7015 · kcadag@medderm.net

  • Clinical Trials Research Institute

    Thousand Oaks, CA 91320

    Site contact: Shawn Ahoubim · +1 888 367 1850 · clinicaltrials@calderm.net

  • Encore Medical Research

    Hollywood, FL 33024

    Site contact: Yeniska Hall · +1 954 400 1725 · yhall@encoremedicalresearch.com

  • Mayo Clinic Jacksonville

    Jacksonville, FL 32224

    Site contact: Jarell C Hughes · +1 904 953 2000 · hughes.jarell@mayo.edu

  • Miami Derm and Laser Institute

    Miami, FL 33173

    Site contact: Swanee Cepero · +1 305 279 6060 · swaneec@miamidermlaser.com

  • Global Clinical Professionals

    St. Petersburg, FL 33714

    Site contact: Madelaine Perez · +1 727 520 1427 · mperez@researchgcp.com

  • Endeavor Health

    Glenview, IL 60077

    Site contact: Jalen Corey · +1 847 663 6814 · jalen.corey@endeavorhealth.org

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, IN 46256

    Site contact: Michelle Riggs · +1 317 516 5030#102 · mgaidzik@ecommunity.com

  • DermAssociates LLC

    Rockville, MD 20850

    Site contact: Meheret Afework · mafework@usdermpartners.com

  • Uni Of Michigan Health System

    Ann Arbor, MI 48109

    Site contact: Nicole Mahn · +1 734 936 5504 · nnechipo@med.umich.edu

  • Hamzavi Dermatology

    Fort Gratiot, MI 48059

    Site contact: Lee Campbell · +1 810 455 1600 · lcampbell@hamzavi.com

  • Revival Research Institute

    Troy, MI 48084

    Site contact: Madhuri Para · +1 248 564 1485 · mpara@rev-research.com

  • Skin Specialists PC

    Omaha, NE 68144

    Site contact: Schyler Schriever · +1 402 334 7546 · Schyler@LovelySkin.com

  • Las Vegas Dermatology

    Las Vegas, NV 89144

    Site contact: Faith Limon · +1 702 456 3120 · ftrujillo@lvderm.com

  • Equity Medical

    The Bronx, NY 10455

    Site contact: Luana Cabreja · lcabreja@equity-med.com

  • Oregon Medical Research Center

    Portland, OR 97223

    Site contact: Megan Lamey · +1 503 245 0315 · mlamey@oregonmedicalresearch.com

  • International Clinical Research Tennessee LCC

    Murfreesboro, TN 37130

    Site contact: +1 615 410 3450

  • Bellaire Dermatology Associates

    Bellaire, TX 77401

    Site contact: Luis Leal Ruiz · +1 713 661 4383 · luis.leal@bellairedermatology.com

  • Center for Clinical Studies

    Houston, TX 77030

    Site contact: Perla Rivas · +1 713 528 8818 · privas@ccstexas.com

  • Austin Inst for Clinical Research

    Pflugerville, TX 78660

    Site contact: Tolga Han · +1 512 279 2545 · tolga.han@atxresearch.com

  • ACRC Trials

    Plano, TX 75024

    Site contact: Jani Taylor · +1 972 354 1520 · JaniT@acrctrials.com

  • Virginia Clinical Research

    Norfolk, VA 23507

    Site contact: Crystal Temple · +1 757 625 0151 · ctemple@vcrinc.org

Study contacts (from the official record)

  • Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
  • Novartis Pharmaceuticals · +41613241111
All dermatology studies in Alabama →
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety… (NCT07431177) | Bored Studies